Andreas Muhs
Keine laufenden Positionen mehr
Karriereverlauf von Andreas Muhs
Ehemalige bekannte Positionen von Andreas Muhs
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AC IMMUNE SA | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 | 22.10.2018 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Corporate Officer/Principal | - | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Ausbildung von Andreas Muhs
Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Statistik
International
Deutschland | 3 |
Schweiz | 2 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AC IMMUNE SA | Health Technology |
Private Unternehmen | 2 |
---|---|
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
- Börse
- Insiders
- Andreas Muhs
- Erfahrung